Table 1.

Clinicopathologic variables in derivation and validation cohorts.

	Derivation (MSKCC) (%)	Validation (European) (%)	p-value
Total number of patients	96	119
Age (median, range)	60 (29–88)	62 (33–85)	NS
Sex
Male	33 (34%)	77 (65%)	< 0.0001
Female	63 (66%)	42 (35%)
Largest Tumor Size > 5cm	22 (23%)	38 (32%)	NS
Primary Nodal Status			NS
N+	56 (58%)	59 (50%)
N−	40 (42%)	51 (43%)
Missing	0	9 (8%)
> 1 tumor	58 (60%)	63 (53%)	NS
DFI < 12 months	51 (53%)	72 (61%)	NS
CEA > 200	8 (8.3%)	13 (11%)	NS
Neoadjuvant chemotherapy	69 (72%)	64 (54%)	< 0.01
Adjuvant chemotherapy	79 (83%)	68 (57%)	< 0.001
Adjuvant HAI chemotherapy	34 (35%)	0 (0%)	< 0.001
Type of resection			< 0.01
Minor (≤ 3 segments)	44 (46%)	76 (64%)
Major (> 3 segments)	52 (54%)	43 (36%)
Median follow up (months)	89	25	< 0.01